Stay informed on developments in cancer and oncology diagnosis, prevention and treatment through these curated webinars. As the race toward a cure for cancer continues, advances in cancer research are constantly revealed as innovation in the field of oncology progresses.
In this webinar, we will be discussing some of our most recent testing using our Cas9 proteins, Cas9 RNP nickases in a variety of human cell types, including primary T-cells. Cas nucleases wh...
In the past two decades a small number of infrequently dividing cells have been proposed as the source of multi-drug resistance during cancer treatment. These cells identified by their expres...
Antibodies have become one of the most important tools in life science research, allowing the detection, quantitation, and determination of changes in proteins and other molecules with respe...
Triple Negative Breast Cancer (TNBC) is an aggressive form of breast cancer, characterized by the characteristic lack of receptors such as human epidermal growth factor receptor-2 (HER-2), t...
Mr. Getson, a USA immigration lawyer, focuses on EB-1A(Extraordinary ability) and NIW (National Interest Waiver) cases, the primary categories in which scientific researchers qualify for gree...
This lecture will encompass the learning experience I have had over my 14,000 RALP cases. We will present an evidence based prospective data collection and analysis of RALP outcomes. We will...
The first small molecule inhibitor of the molecular chaperone Heat Shock Protein 90 (HSP90) was identified more than 20 years ago. Upon determination of the drug binding site and clarificatio...
There has been a great deal of renewed attention in immuno-oncology over the last decade. Therapies for cancer are being developed, approved, and administered that can either initiate,...
Activating mutations in PIK3CA are frequent in human breast cancer, and phosphoinositide 3-kinase alpha (PI3Kα) inhibitors have been approved for therapy. To characterize determinants...
To date the anatomic extent of tumor (TNM-classification) has been by far the most important factors to predict the prognosis of cancer patients. However, this classification provides limited...
Blockade of CTLA-4 and PD-1, members of the B7/CD28 family, have proven to be the most successful cancer immunotherapies to date. While the current therapeutic focus remains on B7/CD28 family...
Effective immunotherapy of pancreatic ductal adenocarcinoma (PDAC) is hampered by the lack of suitable tumor-specific antigens. To address this challenge, we have combined high-throughput fl...
CAR-T translational research demands precise, reproducible, and scalable flow cytometry workflows. Manual centrifugation and antibody preparation steps remain major sources of variability an...
Background: Localized prostate cancer is notable for tumor heterogeneity, and immune heterogeneity within tumor versus benign areas. B7-H3, a member of the B7 superfamily, is highly expresse...
As the most common female malignancy, breast cancer is the most likely reason that a woman will die of cancer around the world. Breast cancer mortality has dropped in the U.S. by 35% since 19...
This webinar covers our latest solutions for improved culture of primary and xenotransplanted tumor cells. Get insights into dissociation of fresh tumor samples into viable single-cell suspe...
In prior work, we have pursued how tumor reactive monoclonal antibody (mAb), together with activators of innate immune cells, like NK cells, can augment antibody dependent cell-mediated cytot...
Cas9 based therapeutics have the potential to revolutionize the treatment of genetic diseases. However, safe and effective methods for delivering Cas9 protein, gRNA and donor DNA need to be...
Colorectal cancer (CRC) is the third most common cancer among Americans, and the second deadliest. Its pathogenesis results from an interplay between environmental factors that influence biol...
Changes in transcriptional regulation are thought to be one of the key drivers of carcinogenesis. Although next-generation sequencer revolutionized transcriptome analysis, there are limitati...
Learning Objectives 1. Identify 3 obstacles that inhibit the immune cell response to cancer. 2. List 3 aspects of T cells antitumor function that can be improved with costimulatory signals....
Learning Objectives 1. Discuss Neoantigen Mechanisms: Gain a comprehensive understanding of the mechanisms by which neoantigens are generated and recognized by the immune system, including t...
With over 265,000 new cases per year and over 50,000 deaths, breast and ovarian cancers represent a significant health burden in the USA. Prior work has demonstrated that CD4 helper T c...
Background: Despite the immunogenicity and safety profile of dendritic cell (DC) vaccines, the importance of vaccine-induced antigen-specific T cell responses is unclear across clinical tria...
A subset of women with ovarian cancer will present with an apparently isolated adnexal mass. Many of these women will have early stage ovarian cancer with a relatively good prognosis. Unfortu...
Metastatic castration resistant prostate cancer (mCRPC) refractory to secondary hormonal treatments such as enzalutamide or abiraterone acetate are the most lethal of prostate cancers. In thi...
In this webinar, we will be discussing some of our most recent testing using our Cas9 proteins, Cas9 RNP nickases in a variety of human cell types, including primary T-cells. Cas nucleases wh...
![Anti-PRAME antibody [EPR20330]](https://d3bkbkx82g74b8.cloudfront.net/eyJidWNrZXQiOiJsYWJyb290cy1pbWFnZXMiLCJrZXkiOiJjb21wYW55X3Byb2R1Y3RfcHJvZmlsZV9pbWFnZV9mMzEwNTY4MGY1NmVmZjU3ZjZhMWRkZTU2M2Q4YjBmODZjMDJkNDE4XzMwMDA3MTg1ODEyLmpwZyIsImVkaXRzIjp7InRvRm9ybWF0IjoianBnIiwicmVzaXplIjp7IndpZHRoIjozMDAsImhlaWdodCI6MzAwLCJmaXQiOiJjb3ZlciIsInBvc2l0aW9uIjoiY2VudGVyIiwiYmFja2dyb3VuZCI6IiNmZmYifSwiZmxhdHRlbiI6eyJiYWNrZ3JvdW5kIjoiI2ZmZiJ9fX0=)
